{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:58:36Z","timestamp":1791986316303,"version":"4.4.0"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,8,19]],"date-time":"2011-08-19T00:00:00Z","timestamp":1313712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (case series)<\/jats:p>\n                    <jats:p>Level of Evidence\u20034<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>TURBT plus full\u2010dose chemoradiotherapy (CRT) against MIBC allow more than 40% of patients to spare the bladder while maintaining survival outcomes comparable to those of radical cystectomy (RC) series, contributing to improvement of the patients\u2019 quality of life. Limitations of these protocols, however, include 1) MIBC recurrence in the preserved bladder mainly due to subclinical residual disease in the original MIBC site, 2) potential lack of curative intervention to regional lymph nodes and 3) increased mortality of salvage RC due to previous high\u2010dose pelvic irradiation. We propose a novel selective bladder\u2010sparing protocol consisting of induction low\u2010dose CRT plus consolidative partial cystectomy with pelvic lymph node dissection, which potentially contributes to overcoming the limitations of the conventional bladder\u2010sparing protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To evaluate oncological outcomes of muscle\u2010invasive bladder cancer (MIBC) patients who were treated with a selective bladder\u2010sparing protocol consisting of induction low\u2010dose chemoradiotherapy (LCRT) plus partial cystectomy (PC) with pelvic lymph node dissection.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>From 1997\u20132010, 183 consecutive patients with cT2\u20134aN0M0 bladder cancer (median age 70 years, women\/men = 46\/137, T2\/3\/4a = 100\/69\/14) underwent debulking transurethral resection followed by LCRT (radiation at 40\u2003Gy to the small pelvis concurrently with two cycles of i.v. cisplatin at 20\u2003mg\/day for 5 days).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Criteria for PC include: (i) essentially solitary MIBC or intravesically circumscribed tumours (\u224825% or less of the bladder in area, excluding the bladder neck and trigone); (ii) no involvement of bladder neck or trigone; and (iii) clinically, no residual disease or minimal amounts of non\u2010invasive disease in the original MIBC site after LCRT; otherwise, radical cystectomy (RC) is recommended.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Primary and secondary endpoints were cancer\u2010specific survival (CSS) and intravesical MIBC recurrence\u2010free survival (MRFS) for bladder\u2010preserved patients, respectively.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Of the 183 patients, 87 (48%) achieved a clinical complete response after LCRT and 65 (36%) met the PC criteria; 46 (25%) patients actually underwent PC, 86 (47%) had RC, and the remaining 51 (28%) had neither PC, nor RC.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Histological examination of the 46 PC specimens showed residual muscle\u2010invasive disease in three (7%).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Overall, 5\u2010year overall survival and CSS rates were 64% and 71%, respectively (median follow\u2010up for survivors of 45 months).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In the 46 PC patients, neither MIBC, nor pelvic recurrence was observed; 5\u2010year CSS and MRFS rates were both 100%.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            In 13 non\u2010PC patients who achieved a complete response after LCRT and who met PC criteria but declined PC, 5\u2010year CSS and MRFS rates were 74% and 81%, respectively; CSS and MRFS were significantly better in the PC group than in the non\u2010PC group (\n                            <jats:italic>P<\/jats:italic>\n                            = 0.025 and 0.002, respectively).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>In the current selective bladder\u2010sparing protocol, one\u2010third of MIBC patients met the PC criteria; when patients from this group underwent PC with pelvic lymph node dissection, their oncological outcomes were excellent.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Consolidative PC potentially reduces MIBC recurrence in the preserved bladder, eventually improving survival in properly selected MIBC patients.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2011.10425.x","type":"journal-article","created":{"date-parts":[[2011,8,19]],"date-time":"2011-08-19T20:20:41Z","timestamp":1313785241000},"page":"860-866","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Selective bladder\u2010sparing protocol consisting of induction low\u2010dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle\u2010invasive bladder cancer: oncological outcomes of the initial 46 patients"],"prefix":"10.1111","volume":"109","author":[{"given":"Fumitaka","family":"Koga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minato","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,19]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22556"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.89"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1298"},{"key":"e_1_2_8_5_2","article-title":"Surgery versus radiotherapy for muscle invasive bladder cancer","volume":"1","author":"Shelley MD","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00718-1"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327480000700403"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.027"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01650-3"},{"key":"e_1_2_8_10_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/jama.1987.03400070069037","article-title":"Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery","volume":"258","author":"Shipley WU","year":"1987","journal-title":"JAMA"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.119"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90306-G"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.08.007"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66440-3"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.666"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000093721.23249.c3"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.11.2901"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00579-8"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00581-X"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)55765-1"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.007"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)55148-4"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08297.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.03.017"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.06.111"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2009.02366.x"},{"key":"e_1_2_8_27_2","volume-title":"Classification of Malignant Tumours","author":"Sobin LH","year":"2002"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67059-9"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.01.004"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.002"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10425.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10425.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:13:54Z","timestamp":1761747234000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10425.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,19]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10425.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10425.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,19]]},"assertion":[{"value":"2011-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}